Tavo Biotherapeutics raises $17M in Series A funding led by Pureos Bioventures to support ongoing clinical development for therapies tackling glaucoma and retinal disease.
Amount Raised
$17 Million
Round Type
Series A
MemphisBiotechnologyHealth CareTherapeuticsInvestors
Description
Tavo Biotherapeutics, based in Laguna Beach, California, raised $17M in Series A funding. The round was led by Pureos Bioventures, with participation from Polaris Partners and existing investor Tau Capital. The company plans to use the funds for ongoing clinical and preclinical development of its TAV-001 and TAV-002 programs. The funding will aid in expanding research capabilities and progressing toward upcoming clinical milestones.
Quick answer
Tavo Biotherapeutics raised $17 Million in a Series A round, dated June 2, 2026. Investors: Polaris Partners, Tau Capital and Pureos Bioventures. Tavo Biotherapeutics is based in Memphis, Tennessee, United States.
- How much did Tavo Biotherapeutics raise?
- Tavo Biotherapeutics raised $17 Million in a Series A round on June 2, 2026.
- Who invested in Tavo Biotherapeutics?
- Polaris Partners, Tau Capital and Pureos Bioventures are named as investors in this round.
- What does Tavo Biotherapeutics do?
- Tavo Biotherapeutics is developing innovative treatments to address critical unmet needs in ophthalmology.
- Where is Tavo Biotherapeutics based and how big is it?
- Tavo Biotherapeutics is based in Memphis, Tennessee, United States. Fundz records about 11 employees.
- Who are the decision-makers at Tavo Biotherapeutics?
- Fundz holds 1 contact at Tavo Biotherapeutics, including the VP of Strategy. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Tavo Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- ME Therapeutics Holdings raised $457K (Post-IPO Equity) on July 17, 2026.
- Sightera Biosciences raised $3.4M (Pre-Seed) on July 17, 2026.
- Georgiamune raised $93M on July 16, 2026.
- Crescent Biopharma raised $8.1M (Post-IPO Equity) on July 15, 2026.
- AdvanCell raised $315M (Series D) on July 15, 2026.
- Draig Therapeutics raised $65M (Series B) on July 14, 2026.
Who to call at Tavo Biotherapeutics, and when
A new round usually means Tavo Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Tavo Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tavo Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tavo Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tavo Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTavo Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.